We’re partnering with Solvias for an in-person panel on CMC challenges in gene therapy, featuring expert insight on regulatory strategy and analytical readiness.
Oct 2, 2025
Panel: A Conversation Regarding Recent Publications for CMC Challenges
Date: 24 October 2025
Location: Magdalen Centre (Thames Room), Robert Robinson Ave, Littlemore, Oxford, UK
Register here
Join experts from across the cell and gene therapy sector for a focused discussion on how to avoid common pitfalls that lead to Complete Response Letters (CRLs) from the FDA, with a particular focus on CMC-related issues.
This event, brought to you by Solvias and eXmoor Pharma, will bring together perspectives from testing, development, and regulatory operations to highlight practical approaches that can help de-risk regulatory submissions and streamline development timelines.
Who should attend?
This session is designed for CMC professionals, regulatory leads, analytical scientists, and gene therapy developers seeking to strengthen their regulatory strategies and reduce the risk of delays.
Panel Participants:
- Clare Blue, Senior CMC Translation Consultant, eXmoor Pharma
- Reginald Clayton, Director – Field Development, Solvias
- Simon Briggs, Director – Advanced Analytics, Orchard Therapeutics
- Erik Splinter, General Manager, Solvias Netherlands
- Rafael Sande, Senior Director – Operations, Solvias
From understanding agency expectations to integrating analytical and CMC strategy early, this is a valuable opportunity to hear expert insight and pose your own questions.
Register for your place today
Let’s Accelerate Your Therapy Together
Whether you're in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.